Literature DB >> 144230

Alterations in dopaminergic receptors in Huntington's disease.

T D Reisine, J Z Fields, L Z Stern, P C Johnson, E D Bird, H I Yamamura.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 144230     DOI： 10.1016/0024-3205(77)90111-4

Source DB:  PubMed          Journal:  Life Sci        ISSN： 0024-3205            Impact factor:   5.037


× No keyword cloud information.
  12 in total

1.  From neuronal inclusions to neurodegeneration: neuropathological investigation of a transgenic mouse model of Huntington's disease.

Authors:  S W Davies; M Turmaine; B A Cozens; A S Raza; A Mahal; L Mangiarini; G P Bates
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

Review 2.  Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease.

Authors:  J H Cha; A S Frey; S A Alsdorf; J A Kerner; C M Kosinski; L Mangiarini; J B Penney; S W Davies; G P Bates; A B Young
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

3.  Scaffold hopping for identification of novel D(2) antagonist based on 3D pharmacophore modelling of illoperidone analogs.

Authors:  Radha Charan Dash; Sharad H Bhosale; Suhas M Shelke; Mugdha R Suryawanshi; Ashish M Kanhed; Kakasaheb R Mahadik
Journal:  Mol Divers       Date:  2011-12-08       Impact factor: 2.943

4.  Validation of the reference tissue model for estimation of dopaminergic D2-like receptor binding with [18F](N-methyl)benperidol in humans.

Authors:  Jo Ann V Antenor-Dorsey; Joanne Markham; Stephen M Moerlein; Tom O Videen; Joel S Perlmutter
Journal:  Nucl Med Biol       Date:  2008-04       Impact factor: 2.408

Review 5.  Dynamic utilization of GABA in substantia nigra: regulation by dopamine and GABA in the striatum, and its clinical and behavioral implications.

Authors:  K Gale; M Casu
Journal:  Mol Cell Biochem       Date:  1981-09-25       Impact factor: 3.396

6.  Extrastriatal dopamine D(2) receptor binding in Huntington's disease.

Authors:  Mouna Esmaeilzadeh; Lars Farde; Per Karlsson; Andrea Varrone; Christer Halldin; Susanna Waters; Joakim Tedroff
Journal:  Hum Brain Mapp       Date:  2010-09-30       Impact factor: 5.038

7.  Human serum Cohn fraction IV (alpha-globulin [correction of globin] enriched) inhibits ligand binding at neurotransmitter receptors in human brain.

Authors:  A C Andorn; M A Pappolla; H Fox; F K Klemens; P A Martello
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

8.  Obsessive-Compulsive Disorder Symptoms in Huntington's Disease: A Case Report.

Authors:  Juan Carlos Molano-Eslava; Angela Iragorri-Cucalón; Gonzalo Ucrós-Rodríguez; Carolina Bonilla-Jácome; Santiago Tovar-Perdomo; David V Herin; Luis Orozco-Cabal
Journal:  Rev Colomb Psiquiatr       Date:  2008-10-01

9.  Dopamine D1 receptor number--a sensitive PET marker for early brain degeneration in Huntington's disease.

Authors:  G Sedvall; P Karlsson; A Lundin; M Anvret; T Suhara; C Halldin; L Farde
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

10.  Dopamine receptor abnormalities in the striatum and pallidum in tardive dyskinesia: a post mortem study.

Authors:  G P Reynolds; J E Brown; J C McCall; A V Mackay
Journal:  J Neural Transm Gen Sect       Date:  1992
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.